March 27, 2024
LungLife AI Inc (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2023 on Thursday 4 April 2024. Investor presentation Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial […]
• Read MoreMarch 22, 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read MoreMarch 21, 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read MoreMarch 5, 2024
Please click here for further details of the Results Announcement.
• Read MoreMarch 4, 2024
Please click here for further details of the Launch Announcement.
• Read MoreJanuary 2, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Successful validation of LungLB® in multi-site, prospective clinical study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces the successful validation of its LungLB® test for indeterminate lung nodules from a prospective, multi-site clinical study in the clinically important small […]
• Read MoreSeptember 28, 2023
LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]
• Read MoreAugust 14, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read More
LungLife AI licensure/accreditation information posted here.